79421-43-5

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(4-Hydroxy-piperidin-1-yl)-benzonitrile is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of drugs with specific therapeutic properties.
Used in Organic Compound Preparation:
As a benzonitrile derivative, 4-(4-Hydroxy-piperidin-1-yl)-benzonitrile is used as a building block in the preparation of other organic compounds, facilitating the creation of a diverse range of chemical entities.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-(4-Hydroxy-piperidin-1-yl)-benzonitrile is utilized as a starting material for the development of drugs that target various biological pathways and diseases, highlighting its importance in advancing therapeutic options.
Used in Chemical Research and Development:
4-(4-Hydroxy-piperidin-1-yl)-benzonitrile is employed in chemical research and development to explore its reactivity, stability, and potential to form new compounds, thereby expanding the horizons of chemical knowledge and application.

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 1194-02-1 4-fluorobenzonitrile 

Downstream Products

• 1334717-80-4 7-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1334717-79-1 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1334718-08-9 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1334718-05-6 6-chloro-N-(4-(4-(4-chlorophenoxy)piperidin-1-yl)benzyl)-2-ethylimidazo[1,2-a]pyridine-3-carboxamide 
• 1334718-10-3 6-chloro-2-ethyl-N-(4-(4-(4-fluorophenoxy)piperidin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1334721-51-5 C₁₃H₁₄N₂ 
• 871013-57-9 C₁₂H₁₈N₂O 
• 281234-93-3 4-(4-hydroxypiperidin-1-yl)benzoic acid 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203

The anti-tubercular activity of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl)imidazo [1,2-a]pyridine-3-carboxamide (Q203) is modified by varying its side chain. In this study, we synthesized Q203 analogues with different side

ANTI-INFECTIVE COMPOUNDS

The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

New oxadiazole derivatives

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: and its use in the treatment of diseases which are susceptible to improvement by sphingosine-1-phosphate (S1P1) receptor agonists.

NEW OXADIAZOLE DERIVATIVES

The present invention relates to an oxadiazole derivative of formula (I)1 or a pharmaceutically acceptable salt or N-oxide thereof: wherein, R1 represents a hydrogen atom, a C1-2 alkyl group or a C3-4 cycloalkyl-C1-2

Trypanocidal activity of conformationally restricted pentamidine congeners

A series of conformationally restricted congeners of pentamidine in which the flexible pentyl bridge of pentamidine was replaced by trans-1,2-bismethylenecyclopropyl, phenyl, pyridinyl, piperazinyl, homopiperazinyl, and piperidinyl groups were synthesized

Synthesis and anti-Pneumocystis carinii activity of piperidine-linked aromatic diimidazolines

A series of novel piperidine-linked aromatic diimidazolines (3-7) have been synthesized as conformationally restricted congeners of the anti-Pneumocystis carinii drug, Pentamidine. These compounds significantly inhibited the growth of Pneumocystis carinii in culture at 1 μg/mL.